Evidence map›Paper›PMID 32231393›Full record

ArticlePloS one2020

Exploring the molecular structures that confer ligand selectivity for galanin type II and III receptors.

Yoo-Na Lee, Arfaxad Reyes-Alcaraz, Seongsik Yun, Cheol Soon Lee, Jong-Ik Hwang, Jae Young Seong

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Yoo-Na LeeThe GPCR laboratory, Graduate School of Biomedical Science, Korea University College of Medicine, Seoul, Republic of Korea.
Arfaxad Reyes-AlcarazThe GPCR laboratory, Graduate School of Biomedical Science, Korea University College of Medicine, Seoul, Republic of Korea.
Seongsik YunThe GPCR laboratory, Graduate School of Biomedical Science, Korea University College of Medicine, Seoul, Republic of Korea.
Cheol Soon LeeGraduate School of Biomedical Science, Korea University College of Medicine, Seoul, Republic of Korea.
Jong-Ik HwangThe GPCR laboratory, Graduate School of Biomedical Science, Korea University College of Medicine, Seoul, Republic of Korea.
Jae Young SeongThe GPCR laboratory, Graduate School of Biomedical Science, Korea University College of Medicine, Seoul, Republic of Korea.ORCID 0000-0002-3312-6924
Korea University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Galanin receptors (GALRs) belong to the superfamily of G-protein coupled receptors. The three GALR subtypes (GALR1, GALR2, and GALR3) are activated by their endogenous ligands: spexin (SPX) and galanin (GAL). The synthetic SPX-based GALR2-specific agonist, SG2A, plays a dual role in the regulation of appetite and depression-like behaviors. Little is known, however, about the molecular interaction between GALR2 and SG2A. Using site-directed mutagenesis and domain swapping between GALR2 and GALR3, we identified residues in GALR2 that promote interaction with SG2A and residues in GALR3 that inhibit interaction with SG2A. In particular, Phe103, Phe106, and His110 in the transmembrane helix 3 (TM3) domain; Val193, Phe194, and Ser195 in the TM5 domain; and Leu273 in the extracellular loop 3 (ECL3) domain of GALR2 provide favorable interactions with the Asn5, Ala7, Phe11, and Pro13 residues of SG2A. Our results explain how SG2A achieves selective interaction with GALR2 and inhibits interaction with GALR3. The results described here can be used broadly for in silico virtual screening of small molecules for the development of GALR subtype-specific agonists and/or antagonists.

Indexed as

Amino Acid SequenceAnimalsHEK293 CellsHumansLigandsMiceMutationProtein DomainsReceptor, Galanin, Type 2Receptor, Galanin, Type 3Substrate SpecificityLigandsReceptor, Galanin, Type 2Receptor, Galanin, Type 3

Identifiers

PMID32231393
PMCPMC7108740
OpenAlexW3013521709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.